Literature DB >> 791316

Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine.

D J Boullin, H F Woods, R P Grimes, D G Grahame-Smith.   

Abstract

1 The aggregation response of platelets induced by 5-HT was greatly increased in psychiatric patients receiving chlorpromazine therapy when compared with normal volunteers and psychiatric patients not receiving chlorpromazine. 2 Platelet aggregation responses to ADP were normal during chlorpromazine therapy, but 5-HT induced aggregation was increased in rate and the typical transient reversible response was converted to an irreversible response in all subjects. This was usually indistinguishable from the ADP response. 3 When chlorpromazine therapy was stopped, plasma concentrations of chlorpromazine, monodesmethylchlorpromazine and chlorpromazine sulphoxide fell rapidly within one week, whereas 5-HT induced platelet aggregation responses became normal after three weeks. The enhanced responses returned when chlorpromazine therapy was re-instituted. 4 It is possible that platelet aggregation responses to 5-HT in vitro could prove to be a useful index of the pharmacological effect of chlorpromazine in vivo.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 791316      PMCID: PMC1402489          DOI: 10.1111/j.1365-2125.1975.tb00468.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Influence of lysolecithin on platelet aggregation initiated by 5-hydroxytryptamine.

Authors:  E M Besterman; M P Gillett
Journal:  Nat New Biol       Date:  1973-02-14

2.  The possible role of metabolites in therapeutic response to chlorpromazine treatment.

Authors:  G Sakalis; T L Chan; S Gershon; S Park
Journal:  Psychopharmacologia       Date:  1973-09-28

3.  Effects of 5-hydroxytryptamine on platelet aggregation.

Authors:  H R Baumgartner; G V Born
Journal:  Nature       Date:  1968-04-13       Impact factor: 49.962

4.  Determination of nanogram quantities of chlorpromazine and some of its metabolites in plasma using gas-liquid chromatography with an electron capture detector.

Authors:  S H Curry
Journal:  Anal Chem       Date:  1968-07       Impact factor: 6.986

5.  Chlorpromazine: concentrations in plasma, excretion in urine and duration of effect.

Authors:  S H Curry
Journal:  Proc R Soc Med       Date:  1971-03

Review 6.  The assay of chlorpromazine and metabolites in blood, urine, and other tissues.

Authors:  E Usdin
Journal:  CRC Crit Rev Clin Lab Sci       Date:  1971-09

7.  A COMPARISON OF PLATELET AGGREGATION PRODUCED BY SEVEN COMPOUNDS AND A COMPARISON OF THEIR INHIBITORS.

Authors:  J R O'BRIEN
Journal:  J Clin Pathol       Date:  1964-05       Impact factor: 3.411

8.  5-Hydroxytryptamine uptake and release in relation to aggregation of rabbit platelets.

Authors:  H R Baumgartner
Journal:  J Physiol       Date:  1969-04       Impact factor: 5.182

9.  The relation between the 5-hydroxytryptamine content and aggregation of rabbit platelets.

Authors:  H R Baumgartner; G V Born
Journal:  J Physiol       Date:  1969-04       Impact factor: 5.182

10.  The mechanism of adenosine diphosphate induced platelet aggregation: binding to platelet receptors and inhibition of binding and aggregation by prostaglandin E 1 .

Authors:  D J Boullin; A R Green; K S Price
Journal:  J Physiol       Date:  1972-03       Impact factor: 5.182

  10 in total
  19 in total

Review 1.  Antipsychotic-induced venous thromboembolism: a review of the evidence.

Authors:  Staffan Hägg; Olav Spigset
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  The reversibility by dipyridamole of the increased sensitivity of in vivo platelet aggregation in rabbits after alloxan.

Authors:  A J Honour; T D Hockaday; J I Mann
Journal:  Br J Exp Pathol       Date:  1976-02

3.  Effects of aspirin and prostaglandin E2 on secondary phase aggregation responses of schizophrenic patients treated with chlorpromazine.

Authors:  D J Boullin; M W Orr
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

4.  Platelet function defects in chronic alcoholism.

Authors:  E W Jones
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-15

5.  Increased platelet aggregation in patients receiving chlorpromazine: responses to 5-hydroxytryptamine, dopamine and N-dimethyl dopamine.

Authors:  D J Boullin; R P Grimes
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

6.  The actions of flupenthixol upon 5-hydroxytryptamine-induced aggregation and the uptake of 5-hydroxytryptamine and dopamine by human blood platelets.

Authors:  D J Boullin; R P Grimes; M W Orr
Journal:  Br J Pharmacol       Date:  1975-12       Impact factor: 8.739

7.  Platelet shape change in patients with psychiatric disorders and treated with phenothiazines, thioxanthines, butyrophenones, benzodiazepines, tricyclic antidepressants and beta-adrenergic blocking agents.

Authors:  D J Boullin
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

8.  The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients.

Authors:  M W Orr; J M Knox; R Allen; M G Gelder; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

9.  The ralationship between changes in 5-HT induced platelet aggregation and clinical state in patients treated with fluphenazine.

Authors:  M W Orr; D J Boullin
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

10.  Resuspension of platelets: enhanced 5-hydroxytryptamine-induced aggregation in chlorpromazine treated patients due to changes in platelet properties.

Authors:  D J Boullin; D G Grahame-Smith; R P Grimes; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.